Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medicskin HoldingsHKSE:08307 54 Return-on-Tangible-Equity is 38.11% as of Mar. 2026. GuruFocus rates HKSE:08307 with a GF Score™ of 54/100 and a GF Value™ of HK$0.18 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 578 Healthcare Providers & Services companies, Medicskin Holdings ranks better than 67.82% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Medicskin Holdings's annualized net income for the quarter that ended in Mar. 2026 was HK$1.80 Mil. Medicskin Holdings's average shareholder tangible equity for the quarter that ended in Mar. 2026 was HK$4.73 Mil. Therefore, Medicskin Holdings's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 38.11%.
The historical rank and industry rank for Medicskin Holdings's Return-on-Tangible-Equity or its related term are showing as below:
HKSE:08307'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -44.6 Med: -1.85 Max: 20.57
Current: 20.57
During the past 13 years, Medicskin Holdings's highest Return-on-Tangible-Equity was 20.57%. The lowest was -44.60%. And the median was -1.85%.
HKSE:08307's Return-on-Tangible-Equity is ranked better than 67.82% of 578
companies
in the Healthcare Providers & Services industry
Industry Median: 10.635
vs HKSE:08307: 20.57
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Medicskin Holdings Return-on-Tangible-Equity Related Terms
Medicskin Holdings Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Medicskin Holdings's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:08307 vs HCA, THC, DVA: Return-on-Tangible-Equity Comparison
For the Medical Care Facilities subindustry, Medicskin Holdings's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medicskin Holdings Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Medicskin Holdings's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Medicskin Holdings's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 38.11% mean?
Medicskin Holdings (HKSE:08307) has a Return-on-Tangible-Equity of 38.11% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Medicskin Holdings and its competitors. According to the industry distribution chart, Medicskin Holdings ranks #186 out of 578 companies in the Healthcare Providers & Services industry, placing it in the top 32.2%.
Is Medicskin Holdings' Return-on-Tangible-Equity too high?
Medicskin Holdings' current Return-on-Tangible-Equity is 38.11%. The Healthcare Providers & Services industry median Return-on-Tangible-Equity is 10.64. Medicskin Holdings' value of 38.11% is 258.3% above this industry median. Based on the distribution chart, Medicskin Holdings ranks #186 out of 578 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Medicskin Holdings has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Medicskin Holdings' Return-on-Tangible-Equity compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Medicskin Holdings ranks #186 out of 578 companies for Return-on-Tangible-Equity. This puts Medicskin Holdings in the upper half of its industry. The industry median Return-on-Tangible-Equity is 10.64. Medicskin Holdings' value of 38.11% is 258.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.64, based on 578 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medicskin Holdings's current Return-on-Tangible-Equity of 38.11% is 258.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Medicskin Holdings and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medicskin Holdings's current Return-on-Tangible-Equity is 38.11%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicskin Holdings stock overvalued right now?
Based on GuruFocus' analysis, Medicskin Holdings (HKSE:08307) is currently considered Possible Value Trap. The stock's GF Value™ is HK$0.18, compared to a current price of HK$0.12 — trading 31.7% below its estimated fair value. The current Return-on-Tangible-Equity is 38.11% and 258.3% above the Healthcare Providers & Services industry median of 10.64. Medicskin Holdings' overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Medicskin Holdings (HKSE:08307), the current Return-on-Tangible-Equity is 38.11% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medicskin Holdings (HKSE:08307) Overvalued in 2026?
Based on GuruFocus' analysis, Medicskin Holdings stock appears to be undervalued.
The current stock price of HK$0.12 is trading 31.7% below its estimated GF Value™ of HK$0.18.
GuruFocus considers Medicskin Holdings to be Possible Value Trap.
Key valuation signals for HKSE:08307:
Return-on-Tangible-Equity: 38.11%
GF Value™: HK$0.18 vs. price of HK$0.12 (31.7% below fair value)
Industry Position: 258.3% above the Healthcare Providers & Services median (#186 of 578)
No single metric tells the full story. See the HKSE:08307 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medicskin Holdings Ltd is a medical skin care service provider. It is engaged in providing services for inter alia, acne, pigmentation, rosacea, dermatitis, eczema and warts, skin rejuvenation, facial sculpturing and body contouring, treatment for acne scars and enlarged pores, removal of undesirable naevi, and hair removal. The company operates through a single segment namely Consultation Service, Prescription and Dispensing Service, and Treatment Services. The company offers services throughout Hong Kong.
54GF Score
Get the complete analysis for HKSE:08307
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08307 has been successfully added to your 
